YiChang HEC ChangJiang Pharmaceutical Co., Ltd.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a YIHCF research report →
Companycj.hec.cn
YiChang HEC ChangJiang Pharmaceutical Co. , Ltd. develops, manufactures, and sells pharmaceutical products in the therapeutic areas of anti-virus, endocrine and metabolic diseases, and cardiovascular diseases in the People's Republic of China.
- CEO
- Juncai Jiang
- IPO
- 2021
- Employees
- 4,618
- HQ
- Yichang, CN
Price Chart
Valuation
- Market Cap
- $643.13M
- P/E
- 25.12
- P/S
- 3.26
- P/B
- 1.43
- EV/EBITDA
- 12.33
- Div Yield
- 10.32%
Profitability
- Gross Margin
- 75.03%
- Op Margin
- 18.11%
- Net Margin
- 12.96%
- ROE
- 5.87%
- ROIC
- 5.16%
Growth & Income
- Revenue
- $3.72B · -40.84%
- Net Income
- $482.71M · -75.78%
- EPS
- $0.55 · -75.66%
- Op Income
- $674.47M
- FCF YoY
- -201.35%
Performance & Tape
- 52W High
- $0.55
- 52W Low
- $0.55
- 50D MA
- $0.55
- 200D MA
- $0.55
- Beta
- 0.11
- Avg Volume
- 139
Get TickerSpark's AI analysis on YIHCF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our YIHCF Coverage
We haven't published any research on YIHCF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate YIHCF Report →